CA3073570C - Delayed-release oral opioid formulations comprising an anionic surfactant and polyethylene oxide - Google Patents

Delayed-release oral opioid formulations comprising an anionic surfactant and polyethylene oxide

Info

Publication number
CA3073570C
CA3073570C CA3073570A CA3073570A CA3073570C CA 3073570 C CA3073570 C CA 3073570C CA 3073570 A CA3073570 A CA 3073570A CA 3073570 A CA3073570 A CA 3073570A CA 3073570 C CA3073570 C CA 3073570C
Authority
CA
Canada
Prior art keywords
anionic surfactant
polyethylene oxide
extended release
release formulations
oral extended
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CA3073570A
Other languages
English (en)
French (fr)
Other versions
CA3073570A1 (en
Inventor
Ozgur Akcan
Richard Mannion
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Purdue Pharma LP
Original Assignee
Purdue Pharma LP
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Purdue Pharma LP filed Critical Purdue Pharma LP
Publication of CA3073570A1 publication Critical patent/CA3073570A1/en
Application granted granted Critical
Publication of CA3073570C publication Critical patent/CA3073570C/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/485—Morphinan derivatives, e.g. morphine, codeine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2031—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyethylene oxide, poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2095—Tabletting processes; Dosage units made by direct compression of powders or specially processed granules, by eliminating solvents, by melt-extrusion, by injection molding, by 3D printing

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Emergency Medicine (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
CA3073570A 2017-08-31 2018-08-30 Delayed-release oral opioid formulations comprising an anionic surfactant and polyethylene oxide Active CA3073570C (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762552521P 2017-08-31 2017-08-31
US62/552,521 2017-08-31
PCT/US2018/048904 WO2019046611A1 (en) 2017-08-31 2018-08-30 PHARMACEUTICAL DOSAGE FORMS

Publications (2)

Publication Number Publication Date
CA3073570A1 CA3073570A1 (en) 2019-03-07
CA3073570C true CA3073570C (en) 2025-07-08

Family

ID=65526129

Family Applications (1)

Application Number Title Priority Date Filing Date
CA3073570A Active CA3073570C (en) 2017-08-31 2018-08-30 Delayed-release oral opioid formulations comprising an anionic surfactant and polyethylene oxide

Country Status (5)

Country Link
US (2) US11911510B2 (enExample)
EP (1) EP3675842A4 (enExample)
JP (1) JP7335870B2 (enExample)
CA (1) CA3073570C (enExample)
WO (1) WO2019046611A1 (enExample)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SA07280459B1 (ar) * 2006-08-25 2011-07-20 بيورديو فارما إل. بي. أشكال جرعة صيدلانية للتناول عن طريق الفم مقاومة للعبث تشتمل على مسكن شبه أفيوني

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6117453A (en) * 1995-04-14 2000-09-12 Pharma Pass Solid compositions containing polyethylene oxide and an active ingredient
US6090411A (en) * 1998-03-09 2000-07-18 Temple University Monolithic tablet for controlled drug release
US20110104214A1 (en) * 2004-04-15 2011-05-05 Purdue Pharma L.P. Once-a-day oxycodone formulations
US20060099256A1 (en) 2002-11-27 2006-05-11 Price James C Microspheres and related processes and pharmaceutical compositions
US7201920B2 (en) 2003-11-26 2007-04-10 Acura Pharmaceuticals, Inc. Methods and compositions for deterring abuse of opioid containing dosage forms
US20050255157A1 (en) * 2004-05-11 2005-11-17 Glenmark Pharmaceuticals Limited Sustained release, mucoadhesive vaginal pharmaceutical compositions
US20080152595A1 (en) * 2004-11-24 2008-06-26 Acura Pharmaceuticals, Inc. Methods and compositions for deterring abuse of orally administered pharmaceutical products
US7671094B2 (en) * 2005-06-27 2010-03-02 Biovail Laboratories International S.R.L. Bupropion hydrobromide and therapeutic applications
US20070281016A1 (en) * 2006-06-06 2007-12-06 Endo Pharmaceuticals Inc., A Delaware Corporation Sustained release oxycodone composition with acrylic polymer and surfactant
CA2671200A1 (en) * 2006-07-21 2008-01-24 Lab International Srl Hydrophilic abuse deterrent delivery system
KR20080076382A (ko) 2007-02-15 2008-08-20 (주)아모레퍼시픽 실로스타졸의 제어방출 제제 및 그 제조방법
DK2285357T3 (da) 2008-05-30 2014-06-02 Ucb Pharma Sa Farmaceutisk sammensætning omfattende brivaracetam
EP2381937A2 (en) * 2008-12-31 2011-11-02 Upsher-Smith Laboratories, Inc. Opioid-containing oral pharmaceutical compositions and methods
WO2012021819A1 (en) * 2010-08-13 2012-02-16 Acura Pharmaceuticals, Inc. Optimized niacin compositions in pharmaceutical products
CA2831218C (en) 2011-03-25 2017-01-17 Purdue Pharma L.P. Controlled release pharmaceutical dosage forms
US9504656B2 (en) * 2013-10-21 2016-11-29 Banner Life Sciences, LLC Pharmaceutical compositions for poorly soluble active ingredients
CA3003950C (en) * 2015-10-23 2020-05-12 Kashiv Pharma Llc Enhanced abuse-deterrent formulations of oxycodone
WO2017136460A1 (en) * 2016-02-01 2017-08-10 Kashiv Pharma Llc Extended release drug formulation with overdose protection and abuse deterrence

Also Published As

Publication number Publication date
CA3073570A1 (en) 2019-03-07
WO2019046611A1 (en) 2019-03-07
JP7335870B2 (ja) 2023-08-30
US20240269078A1 (en) 2024-08-15
EP3675842A4 (en) 2021-05-19
US11911510B2 (en) 2024-02-27
EP3675842A1 (en) 2020-07-08
JP2020532533A (ja) 2020-11-12
US20210077409A1 (en) 2021-03-18

Similar Documents

Publication Publication Date Title
MA29744B1 (fr) Formulations posologiques solides de medicaments presentant une adsorption buccale amelioree
MA29606B1 (fr) Combinaison pharmaceutique comprenant un antibacterien et une substance active choisie parmi le carveol, le thymol, l'eugenol, le borneol et le carvacrol
MA29907B1 (fr) Combinaison pharmaceutique comprenant un agent antifongique et un actif choisi parmi le carveol, l'eugenol, le thymol, le borneol, le carvacrol et les ionones alpha - et beta-
MA29675B1 (fr) Nouvelle formulation pharmaceutique contenant un biguanide et un derive de thiazolidinedione
TNSN01130A1 (fr) Formulations a liberation prolongee pour des secretagogues d'hormone de croissance
DK1526839T3 (da) Orale farmaceutiske former for flydende lægemidler med forbedret biotilgængelighed
ES2184310T3 (es) Formulacion autoemulsionante para compuestos lipofilos acidos.
ES2099094T3 (es) Metodos y composiciones para tratamiento de interacciones hidrofobas patologicas en fluidos biologicos.
MA29273B1 (fr) Combinaison synergique de xolair/omalizumab/e25 et d'un agent immunosuppresseur
UY27642A1 (es) Formas de dosificación de liberación inmediata que contienen dispersiones de fármaco sólido
BRPI0409706A (pt) composição compreendendo um polìmero catiÈnico intensificador de deposição em superfìcies
ATE489942T1 (de) Ternäre nichtlamellare lipidzusammensetzungen
NO951062D0 (no) Germicide detergent-iodsammensetninger som har redusert detergentinnhold
ATE493973T1 (de) Irbesartan enthaltende pharmazeutische zusammensetzung
EP2364692A3 (fr) Compositions comprenant au moins un derive de l'acide naphtoïque, du peroxyde de benzoyle et au moins un agent filmogene, leurs procedes de preparation, et leurs utilisations
MA53927B1 (fr) Composition pharmaceutique pour une administration par voie orale comprenant un dérivé d'aminopyrimidine ou son sel
MA31201B1 (fr) Compositions pharmaceutiques comprenant un agent calcilytique
EA200400628A1 (ru) Таблетки метформина с контролируемым высвобождением активного компонента
ATE516016T1 (de) Selbstemulgierende formulierungen von cetp- hemmern
CA3073570C (en) Delayed-release oral opioid formulations comprising an anionic surfactant and polyethylene oxide
BR0214159A (pt) Sistema farmacêutico radiopaco de liberação prolongada
JOP20220124A1 (ar) مشتقات 1، 2، 4-أوكساديازول كناهضات مستقبلات الكبد x
BRPI0515894A (pt) agente de formação de imagem, composições farmacêutica e radiofarmacêutica, conjugado de um inibidor de metaloproteinase matricial com um ligando, precursor para a preparação da composição radiofarmacêutica, kit para a preparação da composição radiofarmacêutica, e, uso do agente de formação de imagem
BR112022006643A2 (pt) Formulações de liberação controlada de substâncias fisiologicamente ativas altamente lipofílicas
MA29552B1 (fr) Amides a substitution heteroaryle comprenant un groupe de liaison sature et leur utilisation en tant qu'agents

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20230830

EEER Examination request

Effective date: 20230830

EEER Examination request

Effective date: 20230830

EEER Examination request

Effective date: 20230830

EEER Examination request

Effective date: 20230830

EEER Examination request

Effective date: 20230830

EEER Examination request

Effective date: 20230830